JP2002145780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002145780A5 JP2002145780A5 JP2000344317A JP2000344317A JP2002145780A5 JP 2002145780 A5 JP2002145780 A5 JP 2002145780A5 JP 2000344317 A JP2000344317 A JP 2000344317A JP 2000344317 A JP2000344317 A JP 2000344317A JP 2002145780 A5 JP2002145780 A5 JP 2002145780A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- glycosaminoglycans
- weight
- vitamin
- disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims description 29
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 150000002337 glycosamines Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011691 vitamin B1 Substances 0.000 claims description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
- 229940059329 chondroitin sulfate Drugs 0.000 description 6
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 amino sugars Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- PDMUULPVBYQBBK-UHFFFAOYSA-N 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2NC(=O)NC2)=C1 PDMUULPVBYQBBK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000344317A JP4674955B2 (ja) | 2000-11-10 | 2000-11-10 | アミノ糖含有製剤 |
| US09/986,442 US20020099032A1 (en) | 2000-11-10 | 2001-11-08 | Preparations and method of producing the same |
| KR1020010069694A KR100861430B1 (ko) | 2000-11-10 | 2001-11-09 | 제제 및 그의 제조 방법 |
| CN01143682A CN1357328A (zh) | 2000-11-10 | 2001-11-10 | 制剂和生产该制剂的方法 |
| HK02108345.3A HK1046646A1 (zh) | 2000-11-10 | 2002-11-18 | 製劑和生產該製劑的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000344317A JP4674955B2 (ja) | 2000-11-10 | 2000-11-10 | アミノ糖含有製剤 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003316239A Division JP2004002482A (ja) | 2003-09-09 | 2003-09-09 | アミノ糖含有製剤 |
| JP2005183971A Division JP2005281324A (ja) | 2005-06-23 | 2005-06-23 | アミノ糖含有製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002145780A JP2002145780A (ja) | 2002-05-22 |
| JP2002145780A5 true JP2002145780A5 (https=) | 2004-09-24 |
| JP4674955B2 JP4674955B2 (ja) | 2011-04-20 |
Family
ID=18818533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000344317A Expired - Lifetime JP4674955B2 (ja) | 2000-11-10 | 2000-11-10 | アミノ糖含有製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4674955B2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4573542B2 (ja) * | 2004-03-01 | 2010-11-04 | 塩野義製薬株式会社 | ビタミンｂ１誘導体組成物 |
| JP2006036644A (ja) * | 2004-07-22 | 2006-02-09 | Yaizu Suisankagaku Industry Co Ltd | グルコサミン顆粒の製造方法、グルコサミン顆粒及びグルコサミン錠剤 |
| JP2007137842A (ja) * | 2005-11-21 | 2007-06-07 | Medicaraise Corp | 錠核部を外層部で包接した二層形状からなる有核錠 |
| JP2010024181A (ja) * | 2008-07-18 | 2010-02-04 | Takeda Chem Ind Ltd | 固形製剤及びその製造方法 |
| JP5415837B2 (ja) * | 2009-06-12 | 2014-02-12 | アサヒグループホールディングス株式会社 | 圧縮成形性に劣る粉末状の機能性物質から顆粒及び錠剤を製造する方法 |
| JP5826473B2 (ja) * | 2010-09-16 | 2015-12-02 | 協和発酵バイオ株式会社 | 直打用高単位グルコサミン顆粒 |
| JP6196847B2 (ja) * | 2012-08-30 | 2017-09-13 | 興和株式会社 | 防已含有組成物 |
| JP7235193B2 (ja) * | 2017-04-26 | 2023-03-08 | 大正製薬株式会社 | 固形組成物 |
| CN118526501A (zh) * | 2023-07-18 | 2024-08-23 | 杭州博医生物医药科技有限责任公司 | 维生素b1在下调ccl2表达以及在制备骨关节炎药物中的应用 |
-
2000
- 2000-11-10 JP JP2000344317A patent/JP4674955B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090104263A1 (en) | 5-HT4 partial agonist pharmaceutical compositions | |
| US3436454A (en) | Antipyretic and antirheumatic compositions containing an animal mucin | |
| CA2466996A1 (en) | Non-gelatinous capsule shell compositions and capsules using the same | |
| CA2782122A1 (en) | Compositions and methods for stabilized polysaccharide formulations | |
| JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
| JP2002145780A5 (https=) | ||
| ITMI971746A1 (it) | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua | |
| JP2008024700A (ja) | ベルベリン含有水性組成物 | |
| RU2738933C2 (ru) | Мягкие желатиновые капсулы с рН-независимым высвобождением | |
| US3865935A (en) | Tableting of erythromycin base | |
| JP2003160464A (ja) | ヒアルロン酸及び／又はその塩の水溶液の安定化組成物 | |
| JP3748970B2 (ja) | ヒアルロン酸ナトリウム含有水溶液 | |
| EP1694308A1 (en) | Stable formulations of ace inhibitors and methods for preparation thereof | |
| CA2796168A1 (en) | Acetaminophen composition | |
| JP2011525901A (ja) | ロスバスタチンカルシウム含有医薬組成物 | |
| JP4674955B2 (ja) | アミノ糖含有製剤 | |
| JP5101007B2 (ja) | 安定化された医薬製剤 | |
| RU2445950C2 (ru) | Жидкая водная глазная композиция | |
| JP2002145779A5 (https=) | ||
| CA2244097A1 (en) | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid | |
| Knapczyk | Antimycotic buccal and vaginal tablets with chitosan | |
| JP4377123B2 (ja) | 皮膚外用剤組成物 | |
| CA2573985C (en) | A pharmaceutical composition comprising gabapentin | |
| JP2007197410A (ja) | フィルムコーティング錠 | |
| CA2458209A1 (en) | Compositions comprising pectin and ascorbic acid |